New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
08:09 EDTALNY, MRKAlnylam's McSwiggen patent upheld in European opposition proceedings
Alnylam (ALNY) announced that the European Patent Office has upheld the McSwiggen EP 1423406 patent in oral opposition proceedings in Munich, Germany. The McSwiggen patent estate describes chemical modifications of RNAi therapeutics that the company believes are critical for achieving “drug-like” properties in siRNA, the molecules that mediate RNAi. The patent is owned by Alnylam, and was recently obtained through the company’s acquisition of Sirna Therapeutics from Merck (MRK). The McSwiggen patent family comprises a core component of Alnylam’s overall intellectual property estate for the advancement of RNAi therapeutics as a new class of medicines.
News For ALNY;MRK From The Last 14 Days
Check below for free stories on ALNY;MRK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
08:48 EDTMRKNeogen's dairy genomic program to be marketed by Merck
Subscribe for More Information
07:49 EDTALNYAlnylam resumed with an Outperform at Leerink
Subscribe for More Information
September 17, 2014
09:33 EDTMRKMerck announced positive results from Phase 3 data for omarigliptin
Subscribe for More Information
08:31 EDTMRKMerck, Sun Pharma enter into licensing agreement for Tildrakizumab
Merck and Sun Pharmaceutical Industries, through their respective subsidiaries,announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80M. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product. Merck is eligible to receive undisclosed payments associated with regulatory and sales milestones, as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales. The transaction is subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.
September 16, 2014
08:02 EDTALNYAlnylam presents ALN-CC5 pre-clinical data
Subscribe for More Information
07:31 EDTMRKEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:25 EDTMRKMerck price target raised to $72 from $62 at SunTrust
After meeting with Merck's CEO and head of clinical development, SunTrust increased its price target on the company as the firm thinks that it is ideally positioned across five of the fastest growing therapeutic classes. The firm believes that the company's EPS growth rates from 2015-2020 will be three percentage points above Street estimates, while it has a first-mover advantage in oncology. It keeps a Buy rating on the shares.
September 15, 2014
13:30 EDTMRKMerck announces data from pivotal Phase 3 study for odanacatib
Merck announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. Odanacatib is Merck’s investigational once-weekly cathepsin K inhibitor. In the Long-Term Odanacatib Fracture Trial, odanacatib met its primary endpoints and significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with placebo. The rates of adverse events overall in LOFT were generally balanced between patients taking odanacatib and placebo. Adjudicated events of morphea-like skin lesions and atypical femoral fractures occurred more often in the odanacatib group than in the placebo group. Adjudicated major adverse cardiovascular events were generally balanced overall between the treatment groups. There were numerically more adjudicated stroke events with odanacatib than with placebo.
08:01 EDTALNYAlnylam names Karen Anderson as SVP, Chief Human Resources Officer
Subscribe for More Information
07:21 EDTALNYHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 12, 2014
08:02 EDTALNYAlnylam broadens pipeline with ALN-AGT
Alnylam Pharmaceuticals announced that it is broadening its pipeline with ALN-AGT. In a poster presented at the American Heart Association’s High Blood Pressure Research 2014 Scientific Sessions, Alnylam and collaborators at the Charite Universitatsmedizin in Berlin presented results of an ALN-AGT lead molecule in an established preeclamptic rodent model. The study showed that administration of ALN-AGT resulted in knockdown of maternal AGT in the liver without detectable evidence of fetal drug exposure, significantly improved pregnancy-related hypertension, ameliorated preeclamptic sequelae in the mother such as proteinuria, and improved fetal outcomes.
September 10, 2014
16:00 EDTMRKOptions Update; September 10, 2014
Subscribe for More Information
September 8, 2014
16:00 EDTMRKOptions Update; September 8, 2014
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use